ERBB2 and breast carcinoma: An analysis of more than 21,000 early-stage breast cancer patients in Japan revealed that out of 2811 patients whose tumors were HER2-positive before neoadjuvant chemotherapy, 601 patients (21.4%) had lost HER2 expression after therapy.